Intrepid Labs develops the Valiant™ platform, a modular AI-driven robotic lab that selects, prepares, and analyzes drug formulations through semi- and fully autonomous workflows to explore formulation design space rapidly. The platform refines multiple parameters in parallel, reducing formulation timelines from months to days and delivering data-driven optimized formulations. The company also develops proprietary oral and long-acting injectable delivery technologies for small molecules and biologics that are being advanced for licensing. Intrepid has forged partnerships with large pharmaceutical companies, CROs, CDMOs, and smaller biotechs to apply its platform to customer programs. Proceeds from recent financings will expand the team, accelerate development of delivery technologies, and scale commercial operations to meet customer demand. Intrepid was spun out of the University of Toronto and is based in the MaRS Discovery District in Toronto.

Total raised

$7M

Funding rounds

1

Latest round

Seed

Latest activity

May 2025